Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.

Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z.

J Clin Psychiatry. 2011 Jun;72(6):744-50. doi: 10.4088/JCP.09m05659gre. Epub 2010 Oct 19.

PMID:
21034692
2.

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M; EMBOLDEN I (Trial 001) Investigators.

J Clin Psychiatry. 2010 Feb;71(2):150-62. doi: 10.4088/JCP.08m04995gre. Epub 2010 Jan 26.

PMID:
20122369
3.

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH; EMBOLDEN II (Trial D1447C00134) Investigators.

J Clin Psychiatry. 2010 Feb;71(2):163-74. doi: 10.4088/JCP.08m04942gre. Epub 2010 Jan 26.

PMID:
20122366
4.

Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.

van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, Notten PJ, Luteijn ML, Timmermans MA, Vieta E, Nolen WA; LamLit Study Group.

J Clin Psychiatry. 2009 Feb;70(2):223-31. Epub 2008 Dec 30.

PMID:
19200421
5.

Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.

Hirschfeld RM, Weisler RH, Raines SR, Macfadden W; BOLDER Study Group.

J Clin Psychiatry. 2006 Mar;67(3):355-62.

PMID:
16649820
6.

A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.

J Clin Psychiatry. 2012 Jul;73(7):984-91. doi: 10.4088/JCP.11m07230.

PMID:
22901348
7.
8.

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B.

J Clin Psychiatry. 2011 Oct;72(10):1413-22. doi: 10.4088/JCP.09m05934.

PMID:
21672493
9.

An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.

Hirschfeld RM, Eerdekens M, Kalali AH, Canuso CM, Khan AA, Karcher K, Palumbo JM.

Int Clin Psychopharmacol. 2006 Jan;21(1):11-20.

PMID:
16317312
10.
11.

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R.

J Clin Psychopharmacol. 2012 Aug;32(4):470-8. doi: 10.1097/JCP.0b013e31825ccde5.

PMID:
22722504
12.

A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder.

Vieta E, Manuel Goikolea J, Martínez-Arán A, Comes M, Verger K, Masramon X, Sanchez-Moreno J, Colom F.

J Clin Psychiatry. 2006 Mar;67(3):473-7.

PMID:
16649836
13.

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.

Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J.

Am J Psychiatry. 2005 Jul;162(7):1351-60.

PMID:
15994719
14.

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.

Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.

J Clin Psychiatry. 2012 Mar;73(3):353-7. doi: 10.4088/JCP.10m06541. Epub 2011 Sep 20.

PMID:
21939613
15.

Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.

Juruena MF, Ottoni GL, Machado-Vieira R, Carneiro RM, Weingarthner N, Marquardt AR, Fleig SS, Broilo L, Busnello EA.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):94-9. doi: 10.1016/j.pnpbp.2008.10.012. Epub 2008 Oct 31.

PMID:
19007842
16.

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR; BOLDER II Study Group.

J Clin Psychopharmacol. 2006 Dec;26(6):600-9. Erratum in: J Clin Psychopharmacol. 2007 Feb;27(1):51.

PMID:
17110817
17.

Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.

Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA.

J Clin Psychiatry. 2010 Oct;71(10):1363-70. doi: 10.4088/JCP.09m05900gry. Epub 2010 Jul 27.

PMID:
20673554
18.
19.

Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.

Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W; BOLDER Study Group.

Bipolar Disord. 2007 Jun;9(4):413-25.

PMID:
17547587
20.

Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study.

Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, Adli M, Ricken R, Scherk H, Frye MA, Juckel G, Assion HJ, Gitlin M, Whybrow PC, Bauer M.

J Clin Psychiatry. 2014 Feb;75(2):162-8. doi: 10.4088/JCP.12m08305.

PMID:
24345793

Supplemental Content

Support Center